Omega-3 Fatty Acids Supplementation in Children with Autism: A Double-blind Randomized, Placebo-controlled Pilot Study


      There is increasing evidence that fatty acid deficiencies or imbalances may contribute to childhood neurodevelopmental disorders.


      We conducted a randomized, double-blind, placebo-controlled 6-week pilot trial investigating the effects of 1.5 g/d of omega-3 fatty acids (.84 g/d eicosapentaenoic acid, .7 g/d docosahexaenoic acid) supplementation in 13 children (aged 5 to 17 years) with autistic disorders accompanied by severe tantrums, aggression, or self-injurious behavior. The outcome measure was the Aberrant Behavior Checklist (ABC) at 6 weeks.


      We observed an advantage of omega-3 fatty acids compared with placebo for hyperactivity and stereotypy, each with a large effect size. Repeated-measures ANOVA indicated a trend toward superiority of omega-3 fatty acids over placebo for hyperactivity. No clinically relevant adverse effects were elicited in either group.


      The results of this study provide preliminary evidence that omega-3 fatty acids may be an effective treatment for children with autism.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Aman M.G.
        • Singh N.N.
        • Stewart A.W.
        • Field C.J.
        The aberrant behavior checklist: A behavior rating scale for the assessment of treatment effects.
        Am J Ment Defic. 1985; 89: 485-491
        • American Psychiatric Association
        Diagnostic and Statistical Manual of Mental Disorders. 4th ed. American Psychiatric Press, Washington, DC1994
        • Bell J.G.
        • MacKinlay E.E.
        • Dick J.R.
        • MacDonald D.J.
        • Boyle R.M.
        • Glen A.C.
        Essential fatty acids and phospholipase A2 in autistic spectrum disorders.
        Prostaglandins Leukot Essent Fatty Acids. 2004; 71: 201-204
        • Berger G.E.
        • Wood S.J.
        • Pantelis C.
        • Velakoulis D.
        • Wellard R.M.
        • McGorry P.D.
        Implications of lipid biology for the pathogenesis of schizophrenia.
        Aust N Z J Psychiatry. 2002; 36: 355-366
        • Bolte S.
        • Poustka F.
        Diagnostic Observation Scale for Autistic Disorders: Initial results of reliability and validity.
        Z Kinder Jugendpsychiatr Psychother. 2004; 32: 45-50
        • Gesch C.B.
        • Hammond S.M.
        • Hampson S.E.
        • Eves A.
        • Crowder M.J.
        Influence of supplementary vitamins, minerals and essential fatty acids on the antisocial behaviour of young adult prisoners.
        Br J Psychiatry. 2002; 181: 22-28
        • Hamazaki K.
        • Itomura M.
        • Huan M.
        • Nishizawa H.
        • Sawazaki S.
        • Tanouchi M.
        • et al.
        Effect of omega-3 fatty acid-containing phospholipids on blood catecholamine concentrations in healthy volunteers: A randomized, placebo-controlled, double-blind trial.
        Nutrition. 2005; 21: 705-710
        • Helland I.B.
        • Smith L.
        • Saarem K.
        • Saugstad O.D.
        • Drevon C.A.
        Maternal supplementation with very-long-chain n-3 fatty acids during pregnancy and lactation augments children’s IQ at 4 years of age.
        Pediatrics. 2003; 111: e39-e44
        • Hibbeln J.R.
        • Linnoila M.
        • Umhau J.C.
        • Rawlings R.
        • George D.T.
        • Salem Jr, N.
        Essential fatty acids predict metabolites of serotonin and dopamine in cerebrospinal fluid among healthy control subjects, and early- and late-onset alcoholics.
        Biol Psychiatry. 1998; 44: 235-242
        • Lingjaerde O.
        • Ahlfors U.G.
        • Bech P.
        • Dencker S.J.
        • Elgen K.
        The UKU side effect rating scale.
        Acta Psychiatr Scand Suppl. 1987; 334: 1-100
        • McDougle C.J.
        • Scahill L.
        • Aman M.G.
        • McCracken J.T.
        • Tierney E.
        • Davies M.
        • et al.
        Risperidone for the core symptom domains of autism: Results from the study by the Autism Network of the Research Units on Pediatric Psychopharmacology.
        Am J Psychiatry. 2005; 162: 1142-1148
        • Posey D.J.
        • McDougle C.J.
        Pharmacotherapeutic management of autism.
        Expert Opin Pharmacother. 2001; 2: 587-600
        • Poustka F.
        • Lisch S.
        • Ruhl D.
        • Sacher A.
        • Schmotzer G.
        • Werner K.
        The standardized diagnosis of autism, Autism Diagnostic Interview–Revised: Interrater reliability of the German form of the interview.
        Psychopathology. 1996; 29: 145-153
        • Research Units on Pediatric Psychopharmacology Autism Network
        Risperidone in children with autism and serious behavioral problems.
        N Engl J Med. 2002; 347: 314-321
        • Richardson A.J.
        Long-chain polyunsaturated fatty acids in childhood developmental and psychiatric disorders.
        Lipids. 2004; 39: 1215-1222
        • Richardson A.J.
        • Montgomery P.
        The Oxford-Durham study: A randomized, controlled trial of dietary supplementation with fatty acids in children with developmental coordination disorder.
        Pediatrics. 2005; 115: 1360-1366
        • Vancassel S.
        • Durand G.
        • Barthelemy C.
        • Lejeune B.
        • Martineau J.
        • Guilloteau D.
        • et al.
        Plasma fatty acid levels in autistic children.
        Prostaglandins Leukot Essent Fatty Acids. 2001; 65: 1-7
        • Wainwright P.E.
        Dietary essential fatty acids and brain function: A developmental perspective on mechanisms.
        Proc Nutr Soc. 2002; 61: 61-69
        • Willatts P.
        • Forsyth J.S.
        • DiModugno M.K.
        • Varma S.
        • Colvin M.
        Effect of long-chain polyunsaturated fatty acids in infant formula on problem solving at 10 months of age.
        Lancet. 1998; 352: 688-691
        • Young G.
        • Conquer J.
        Omega-3 fatty acids and neuropsychiatric disorders.
        Reprod Nutr Dev. 2005; 45: 1-28
        • Zanarini M.C.
        • Frankenburg F.R.
        Omega-3 fatty acid treatment of women with borderline personality disorder: A double-blind, placebo-controlled pilot study.
        Am J Psychiatry. 2003; 160: 167-169